FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $518.65M
Company Location Date Amt. (M) Details

4-Antibody AG Basel, Switzerland 1/16/07 CHF17
(US$13.6)
4-Antibody raised CHF17M in its Series A round led by Advent Venture Partners; other investors were Biomedinvest AG, Grazia Equity GmbH, Life Sciences Partners and Mulligan Biocapital AG, as well as several private investors
Althea
Technologies
Inc.
San Diego 1/9/07 $23 Investing in the Series C financing investment were funds managed by Telegraph Hill Partners
Avesthagen
Pvt. Ltd.
Bangalore 1/31/07** €25 (US$32.3) Investors in the round included Fidelity International, Limagrain Group, Daninvest and Bennett Coleman
Ception
Therapeutics
Inc.
Malvern, Pa. 1/30/07 $63 Series C round was led by Essex Woodlands Health Ventures and included participation by Investor Growth Capital, MDS Life Sciences Technology Fund II, New Science Ventures and Aperture Venture Partners
Conatus
Pharmaceuticals
Inc.
San Diego 1/3/07 $5.5 Conatus closed on the the first $5.5M in what was expected to be a $27.5M financing round; the round was led by Aberdare Ventures, and included Advent Venture Partners, Bay City Capital and Gilde Healthcare Partners
Cylene
Pharmaceuticals
Inc.
San Diego 1/23/07 $44 Cylene raised $44M through a Series C round; investors were HBM BioVentures (Cayman) Ltd., Lilly Ventures, Sanderling Ventures, Novartis BioVenture Fund, BioVentures Investors, Research Corp. Technologies, Mitsui & Co. Venture Partners and Celgene Corp.
Cytochroma
Inc.
Markham, Ontario 1/17/07 C$21 (US$17.9) Cytochroma raised C$21M in a venture round led by VenGrowth Advanced Life Sciences Fund, Novo A/S and GeneChem Technologies Venture Fund
EyeGate
Pharma Inc.
Paris 1/17/07 $2 Company raised $2M more, bringing the total raised in its Series B round to $12M; the first tranche was co-led by Innoven Partenaires and Ventech
F-star Vienna, Austria 1/8/07 €1.5 (US$1.95) The seed financing was provided by Atlas Venture
Horizon
Therapeutics
Inc.*
Palo Alto, Calif. 1/4/07 $15 Scale Venture Partners led the Series B round, which also included other Series A investors Sutter Hill Ventures and Pequot Ventures
InteKrin Inc. Palo Alto, Calif. 1/11/07 $23 The Series A financing was led by Sofinnova Ventures and included OrbiMed Advisors and Vivo Ventures, as well as existing investors Asset Management and Sears Capital Management
Juvaris
BioTherapeutics
Inc.
Pleasanton, Calif. 1/8/07 $6 The $6M was the first closing of what was expected to be a $12M Series A financing; it was provided by Kleiner Perkins Caufield & Byers Pandemic & Biodefense Fund
NanoMed
Pharmaceuticals
Inc.
Kalamazoo, Mich. 1/31/07 ND Company completed the second close of its Series A round; the first close occurred in July 2006; SWMF Life Science Venture Fund was the primary investor
Movetis NV Vosselaar, Belgium 1/8/07 €49 (US$63.7) The Series A financing round was led by Sofinnova Partners and Life Sciences Partners, and included Sofinnova Ventures, KBC, GIMV, Quest for Growth and BIP Investment Partners
Novexel SA Paris 1/8/07 €50 (US$65) The Series B financing was led by Edmond de Rothschild Investment Parnters and included other new investors Goldman Sachs, Neomed and NIF SMBC, as well as existing investors Atlas Venture, Sofinnova, Abingworth, 3i, Novo A/S and BIT
Osprey
Pharmaceuticals
Ltd.
Montreal 1/30/07 $9 The financing included $6M in tranched convertible debt from existing investors and $3M in venture debt from MMV Capital; the convertible debt placement was led by GeneChem Therapeutics Venture Fund and included Desjardins Capital Regional et Cooperatif, BDC Venture Capital and Western Technology Seed Investment Fund
Phase
Bioscience
Inc.
Durham, N.C. 1/3/07 ND Johnson & Johnson Development Corp. provided the first tranche in the company's Series B financing
Proprius
Pharmaceuticals
Inc.
San Diego 1/8/07 $11 The Series A financing was led by Atlas Venture, along with Forward Ventures and CDIB Bio- Science Venture Management, and included previous investors Fog City Fund and Windamere Venture Partners
Semafore
Pharmaceuticals
Inc.
Indianapolis 1/5/07 $9.5 The Series B financing round included new and existing investors
Sequoia
Pharmaceuticals
Inc.
Gaithersburg, Md. 1/8/07 $35 The Series C financing round was led by The Wellcome Trust and included other existing investors Healthcare Venture, Sofinnova Partners and Aberdare Ventures, and new investor MedImmune Ventures Inc.
Symphogen AS Copenhagen, Denmark 1/31/07 €5
(US$6.5)
Symphogen added $6.5M to the latest round, bringing the total raised to $85M; the new funding came from Gilde Healthcare Partners
Tigris
Pharmaceuticals
Inc.
Bonita Springs, Fla. 1/16/07 $16 Tirgris raised $16M in a Series B round led by NGN Capital LLC; other investors were Wexford Capital LLC and Bushido Capital Partners; Riverbank Capital Securities Inc. was placement agent
Variation
Biotechnologies
Inc.
Ottawa, Ontario 1/4/07 $35.7 The Series A financing round was led by Clarus Ventures, and included ARCH Venture Partners, 5AM Ventures and existing seed investors
Xcellerex Inc. Marlborough, Mass. 1/26/07 $20 The Series B round was led by SCG Group and Kleiner Perkins

Notes:
Currency conversions are based on exchange rates at the time of the deal.
ND = Not disclosed.